Topic: Growth Stocks

55 straight years of rising dividends for Johnson & Johnson

A Member of Pat McKeough’s Inner Circle recently requested his opinion on one of the best known consumer stocks in North America.

Johnson & Johnson gets almost half of its revenue from its pharmaceutical business. Investors can underestimate the risk of drug stocks, says Pat, due to the high costs, regulatory hurdles and fierce competition. On the other hand, the long-term outlook for the company remains positive: it trades at around 15 times forecast earnings and has raised its dividend for 55 consecutive years.

Q: Dear Pat: Johnson & Johnson seems to be a widely recommended stock. Please, may I have your analysis?


Where investors lose more money

“Overall, investors lose more money to conflicts of interest than to any other single risk. That’s not a comment about the average broker’s sense of ethics. It’s simply a matter of frequency of exposure times risk per exposure. For example, suppose you tell your broker that you have some money and you want to invest it aggressively…”
Whether you’re a Do-It-Yourself investor or have someone else handle your money, you will find many keys to building the retirement you want in Pat McKeough’s special report. Four decades of proven experience have gone into “Wealth Management and Retirement Planning”.

A: JOHNSON & JOHNSON (symbol JNJ on New York; www.jnj.com) operates through three major businesses:

Pharmaceutical (47% of revenue) makes anti-infective, antipsychotic, contraceptive, dermatological and gastrointestinal drugs;

Medical devices and diagnostics (35%) sells equipment for joint reconstruction and managing circulatory diseases;

Consumer (18%) makes over-the-counter products such as Johnson’s baby-care items, Band-Aid bandages, Tylenol and Motrin painkillers, Listerine mouthwash and Neutrogena skin cream.

Johnson & Johnson’s revenue rose 4.2%, from $71.3 billion in 2013 to $74.3 billion in 2014. Revenue dropped 5.7%, to $70.1 billion in 2015 before rising 2.6% to $71.9 billion for 2016. In 2017, revenue rose again, by 6.4% to $76.5 billion.

Johnson & Johnson’s earnings per share rose 18.5%, from $4.81 in 2013 to $5.70 in 2014. Profit then slipped 3.9% to $5.48 a share in 2015 before rebounding 8.2% to $5.93 in 2016. In 2017, earnings per share were only $0.47 due to a $13.6 billion charge associated with the new U.S. tax legislation. However, excluding that charge and all other unusual items, earnings per share rose 8.5%, to $7.30 per share in 2017, from $6.73 per share in 2016.

In June 2017, Johnson & Johnson paid $30 billion in cash to acquire Actelion Ltd., a Swiss biotech company best known for its drug therapies to treat high blood pressure.

As part of the agreement, Actelion spun off its research & development business. Idorsia Ltd., now trades on the Swiss stock exchange. Johnson & Johnson has held on to 9.9% of that new firm and the former parent also has the option of buying an additional 22.1% stake.

Growth stocks: Research spending rises 16% year over year

Johnson & Johnson continues to spend heavily on research and development. In 2017, it spent $10.6 billion (13.8% of total revenue) on research. That’s up 16.0% from $9.1 billion (12.7% of total revenue) in 2016.

The company’s balance sheet is strong: its long-term debt of $30.7 billion (on December 31, 2017) is just 8% of its market cap. It also holds cash of $18.3 billion.

We’ve always felt that many investors underestimate the risk of drug stocks, and overestimate their potential. They also overlook the huge costs drugmakers face in creating a new product and gaining regulatory approval for it. Investors are just as likely to overlook the limited time that drugmakers have to recoup their investments before a patent expires or a better drug comes along.

As well, many consumers now opt for cheaper store brands over the kind of name-brand products Johnson & Johnson sells. That requires the company to spend more and more heavily on marketing.

Moreover, big acquisitions, such as Actelion, may come with hidden problems that can delay the expected benefits.

Still, the long-term outlook for Johnson & Johnson is positive. The company will probably earn $8.10 a share in 2018. The stock trades at 15.6 times that estimate. The $3.36 dividend yields 2.5%. Johnson & Johnson has increased its payout annually for the past 55 years.

Inner Circle recommendation: Johnson & Johnson is okay to hold.

For our recent report on a Canadian growth stock with some competitive challenges, read High yield for Superior Plus could be undercut by low gas prices.

For our views on how to focus on stocks with real growth in store, read Stocks Expected to Rise: How to pick the ones with the best growth prospects.

Comments

Tell Us What YOU Think

You must be logged in to post a comment.

Please be respectful with your comments and help us keep this an area that everyone can enjoy. If you believe a comment is abusive or otherwise violates our Terms of Use, please click here to report it to the administrator.